The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ...

A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...

The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...

The two highest doses of the JAK1/TYK2 inhibitor QY201 led to 75% skin clearance rates of 81-85%. In addition, 64-71% of patients met the secondary endpoint of clear/almost clear skin by ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of ...